Exane Derivatives’s Neurocrine Biosciences NBIX Stock Holding History

Exane Derivatives’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$106K	Buy	1,084 +1,081	+36,033%	+$99.8K	0.06%	260
2022 Q1	$281	Hold	3	–	–	﹤0.01%	929
2021 Q4	$256	Hold	3	–	–	﹤0.01%	821
2021 Q3	$288	Hold	3	–	–	﹤0.01%	993
2021 Q2	$292	Hold	3	–	–	﹤0.01%	997
2021 Q1	$292	Hold	3	–	–	﹤0.01%	845
2020 Q4	$288	Sell	3 -44	-94%	-$4.25K	﹤0.01%	777
2020 Q3	$4.52K	Hold	47	–	–	﹤0.01%	513
2020 Q2	$5.73K	Hold	47	–	–	﹤0.01%	442
2020 Q1	$4.07K	Hold	47	–	–	﹤0.01%	464
2019 Q4	$5.04K	Sell	47 -56	-54%	-$5.86K	﹤0.01%	438
2019 Q3	$9.28K	Sell	103 -5,000	-98%	-$467K	﹤0.01%	436
2019 Q2	$431K	Buy	5,103 +246	+5%	+$20.2K	0.08%	184
2019 Q1	$428K	Buy	4,857 +4,372	+901%	+$365K	0.08%	162
2018 Q4	$34.6K	Buy	485 +484	+48,400%	+$46.4K	0.01%	398
2018 Q3	$123	Sell	1 -1	-50%	-$113	﹤0.01%	615
2018 Q2	$198	Sell	2 -23	-92%	-$2.06K	﹤0.01%	590
2018 Q1	$2.02K	Sell	25 -140	-85%	-$11.8K	﹤0.01%	445
2017 Q4	$12.8K	Sell	165 -640	-80%	-$43.7K	﹤0.01%	391
2017 Q3	$49.3K	Buy	+805	New	+$42.5K	0.01%	308

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Exane Derivatives's NBIX Position: Q2 2022 in Review

Exane Derivatives increased its Neurocrine Biosciences (NBIX) stake by 36,033% in Q2 2022, buying an estimated $99.8K and bringing the position to 1,084 shares worth $106K. The position accounts for 0.06% of the portfolio, ranked #260.

Exane Derivatives first reported a position in NBIX in Q3 2017 and has held it in 20 quarters since. The position peaked at $431K in Q2 2019. 438 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

Exane Derivatives held 1,084 shares of Neurocrine Biosciences worth $106K as of Q2 2022.
Exane Derivatives bought 1,081 Neurocrine Biosciences shares in Q2 2022, an estimated $99.8K.
Neurocrine Biosciences made up 0.06% of Exane Derivatives's portfolio in Q2 2022, its #260 holding.
Exane Derivatives first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 20 quarters since.
Exane Derivatives's Neurocrine Biosciences position peaked at $431K in Q2 2019.
438 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.